Abstract

Background. In the last decade, therapy using multipotent mesenchymal stromal cells (MSCs) has offered hope for regenerating the lungs of preterm babies with chronic lung disease. Due to similar disease mechanisms, it is logical to explore the potential impact of MSC therapy on pulmonary hypoplasia in congenital diaphragmatic hernia. Furthermore, MSCs may also contribute to the regeneration of the intestines affected by adhesive small bowel obstruction in patients with congenital diaphragmatic hernia.

Case presentation. A female newborn, delivered at 32 weeks and six days gestational age, was diagnosed with a left congenital diaphragmatic hernia. After surgical repair and respiratory/nutritional support for 39 days, she was still dependent on a ventilator and total parenteral nutrition. Two MSC treatments were given a week apart: 10 million cells/kg intratracheally and 5 million cells/kg intravenously. She was extubated, and her enteral nutrition improved after the treatment. No side effects were detected. We present the first documented case using MSCs derived from the umbilical cord to simultaneously treat pulmonary hypoplasia and adhesive small bowel obstruction of congenital diaphragmatic hernia.

Conclusion. Although MSC treatment is very promising for pulmonary hypoplasia and adhesive small bowel disease of congenital diaphragmatic hernia, much more needs to be learned about potential side effects, appropriate dosage, and the optimal method of administration.

Keywords: mesenchymal stromal cell, congenital diaphragmatic hernia

Copyright and license

Copyright © 2024 The Author(s). This is an open access article distributed under the Creative Commons Attribution License (CC BY), which permits unrestricted use, distribution, and reproduction in any medium or format, provided the original work is properly cited.

How to cite

1.
Yıldırım Ş, Kandırıcı A. Multipotent mesenchymal stromal cell therapy for a neonate with congenital diaphragmatic hernia and adhesive small bowel obstruction. Turk J Pediatr 2024; 66: 630-636. https://doi.org/10.24953/turkjpediatr.2024.4856

References

  1. Wright JC, Budd JL, Field DJ, Draper ES. Epidemiology and outcome of congenital diaphragmatic hernia: a 9-year experience. Paediatr Perinat Epidemiol 2011; 25: 144-149. https://doi.org/10.1111/j.1365-3016.2010.01172.x
  2. Sakurai Y, Azarow K, Cutz E, Messineo A, Pearl R, Bohn D. Pulmonary barotrauma in congenital diaphragmatic hernia: a clinicopathological correlation. J Pediatr Surg 1999; 34: 1813-1817. https://doi.org/10.1016/s0022-3468(99)90319-6
  3. Terui K, Tazuke Y, Nagata K, et al. Weight gain velocity and adequate amount of nutrition for infants with congenital diaphragmatic hernia. Pediatr Surg Int 2021; 37: 205-212. https://doi.org/10.1007/s00383-020-04785-y
  4. Williams E, Greenough A. Respiratory support of infants with congenital diaphragmatic hernia. Front Pediatr 2021; 9: 808317. https://doi.org/10.3389/fped.2021.808317
  5. Razak A, Lei D, McDonald CA, Hunt RW, Miller SL, Malhotra A. Allogeneic Cell Therapy Applications in Neonates: A Systematic Review. Stem Cells Transl Med 2023; 12: 651–664. https://doi.org/10.1093/stcltm/szad048.
  6. Yuniartha R, Alatas FS, Nagata K, et al. Therapeutic potential of mesenchymal stem cell transplantation in a nitrofen-induced congenital diaphragmatic hernia rat model. Pediatr Surg Int 2014; 30: 907-914. https://doi.org/10.1007/s00383-014-3576-9
  7. Takayama S, Sakai K, Fumino S, et al. An intra-amniotic injection of mesenchymal stem cells promotes lung maturity in a rat congenital diaphragmatic hernia model. Pediatr Surg Int 2019; 35: 1353-1361. https://doi.org/10.1007/s00383-019-04561-7
  8. Chalphin AV, Tracy SA, Lazow SP, Kycia I, Zurakowski D, Fauza DO. Congenital diaphragmatic hernia as a potential target for transamniotic stem cell therapy. J Pediatr Surg 2020; 55: 249-252. https://doi.org/10.1016/j.jpedsurg.2019.10.033
  9. Karacanoğlu D, Çeleğen M, Yavuz S, Katlan B, Kesici S, Bayrakçı B. An inspiring horizon to congenital diaphragmatic hernia with mesenchymal stem cell therapy. Chest 2022; 161(Suppl): A548. https://doi.org/10.1016/j.chest.2022.04.082
  10. Zahn KB, Franz AM, Schaible T, et al. Small bowel obstruction after neonatal repair of congenital diaphragmatic hernia-incidence and risk-factors identified in a large longitudinal cohort-study. Front Pediatr 2022; 10: 846630. https://doi.org/10.3389/fped.2022.846630
  11. Macchini F, Raffaeli G, Amodeo I, et al. Recurrence of congenital diaphragmatic hernia: risk factors, management, and future perspectives. Front Pediatr 2022; 10: 823180. https://doi.org/10.3389/fped.2022.823180
  12. Kobayashi H, Yamataka A, Okazaki T, Lane GJ, Puri P, Miyano T. Increased levels of circulating adhesion molecules in neonates with congenital diaphragmatic hernia complicated by persistent pulmonary hypertension. Pediatr Surg Int 2004; 20: 19-23. https://doi.org/10.1007/s00383-003-1072-8
  13. Sakrani NF, Hamza E, Ahmed HA, Corbally MT. Surgical management of necrotizing enterocolitis following congenital diaphragmatic hernia repair. Bahrain Medical Bulletin 2015; 37: 253-255. https://doi.org/10.12816/0047415
  14. Shanbhogue LK, Tam PK, Lloyd DA. Necrotizing enterocolitis following operation in the neonatal period. Br J Surg 1991; 78: 1045-1047. https://doi.org/10.1002/bjs.1800780906
  15. Koh YH, Cooksey R, Prager P. Early onset necrotising enterocolitis in association with congenital diaphragmatic hernia in a term baby. BMJ Case Rep 2018; 2018: bcr2018224854. https://doi.org/10.1136/bcr-2018-224854
  16. Markel TA, Underwood MA. Preface: The NEC Society. Semin Pediatr Surg 2018; 27: 1-2. https://doi.org/10.1053/j.sempedsurg.2017.11.001
  17. Bazacliu C, Neu J. Necrotizing enterocolitis: long term complications. Curr Pediatr Rev 2019; 15: 115-124. https://doi.org/10.2174/1573396315666190312093119
  18. Di SJ, Wu SY, Liu TJ, Shi YY. Stem cell therapy as a promising strategy in necrotizing enterocolitis. Mol Med 2022; 28: 107. https://doi.org/10.1186/s10020-022-00536-y
  19. Merimi M, El-Majzoub R, Lagneaux L, et al. The therapeutic potential of mesenchymal stromal cells for regenerative medicine: current knowledge and future understandings. Front Cell Dev Biol 2021; 9: 661532. https://doi.org/10.3389/fcell.2021.661532
  20. Krueger TEG, Thorek DLJ, Denmeade SR, Isaacs JT, Brennen WN. Concise review: mesenchymal stem cell-based drug delivery: the good, the bad, the ugly, and the promise. Stem Cells Transl Med 2018; 7: 651-663. https://doi.org/10.1002/sctm.18-0024
  21. Chang C, Yan J, Yao Z, Zhang C, Li X, Mao HQ. Effects of mesenchymal stem cell-derived paracrine signals and their delivery strategies. Adv Healthc Mater 2021; 10: e2001689. https://doi.org/10.1002/adhm.202001689
  22. Ramesh S, Daniel D, Götherström C, Madhuri V. Trophic effects of multiple administration of mesenchymal stem cells in children with osteogenesis imperfecta. Clin Transl Med 2021; 11: e385. https://doi.org/10.1002/ctm2.385
  23. Gong C, Chang L, Sun X, et al. Infusion of two-dose mesenchymal stem cells is more effective than a single dose in a dilated cardiomyopathy rat model by upregulating indoleamine 2,3-dioxygenase expression. Stem Cell Res Ther 2022; 13: 409. https://doi.org/10.1186/s13287-022-03101-w
  24. Caplan H, Olson SD, Kumar A, et al. Mesenchymal stromal cell therapeutic delivery: translational challenges to clinical application. Front Immunol 2019; 10: 1645. https://doi.org/10.3389/fimmu.2019.01645
  25. Miceli V, Zito G, Bulati M, et al. Different priming strategies improve distinct therapeutic capabilities of mesenchymal stromal/stem cells: potential implications for their clinical use. World J Stem Cells 2023; 15: 400-420. https://doi.org/10.4252/wjsc.v15.i5.400
  26. Fischer UM, Harting MT, Jimenez F, et al. Pulmonary passage is a major obstacle for intravenous stem cell delivery: the pulmonary first-pass effect. Stem Cells Dev 2009; 18: 683-692. https://doi.org/10.1089/scd.2008.0253
  27. Sahni M, Bhandari V. Recent advances in understanding and management of bronchopulmonary dysplasia. F1000Res 2020; 9(Faculty Rev): 703. https://doi.org/10.12688/f1000research.25338.1
  28. Nobuhara KK, Wilson JM. Pathophysiology of congenital diaphragmatic hernia. Semin Pediatr Surg 1996; 5: 234-242.
  29. Wu Z, Zhang S, Zhou L, et al. Thromboembolism induced by umbilical cord mesenchymal stem cell infusion: a report of two cases and literature review. Transplant Proc 2017; 49: 1656-1658. https://doi.org/10.1016/j.transproceed.2017.03.078
  30. Jung JW, Kwon M, Choi JC, et al. Familial occurrence of pulmonary embolism after intravenous, adipose tissue-derived stem cell therapy. Yonsei Med J 2013; 54: 1293-1296. https://doi.org/10.3349/ymj.2013.54.5.1293
  31. Suzuki K, Sun R, Origuchi M, et al. Mesenchymal stromal cells promote tumor growth through the enhancement of neovascularization. Mol Med 2011; 17: 579-587. https://doi.org/10.2119/molmed.2010.00157
  32. Harrell CR, Volarevic A, Djonov VG, Jovicic N, Volarevic V. Mesenchymal stem cell: a friend or foe in anti-tumor immunity. Int J Mol Sci 2021; 22: 12429. https://doi.org/10.3390/ijms222212429
  33. Chen G, Yue A, Ruan Z, et al. Human umbilical cord-derived mesenchymal stem cells do not undergo malignant transformation during long-term culturing in serum-free medium. PLoS One 2014; 9: e98565. https://doi.org/10.1371/journal.pone.0098565
  34. Baranovskii DS, Klabukov ID, Arguchinskaya NV, et al. Adverse events, side effects and complications in mesenchymal stromal cell-based therapies. Stem Cell Investig 2022; 9: 7. https://doi.org/10.21037/sci-2022-025
  35. Zhang S, Mulder C, Riddle S, Song R, Yue D. Mesenchymal stromal/stem cells and bronchopulmonary dysplasia. Front Cell Dev Biol 2023; 11: 1247339. https://doi.org/10.3389/fcell.2023.1247339